340 related articles for article (PubMed ID: 10878294)
1. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
2. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action for leflunomide in rheumatoid arthritis.
Fox RI; Herrmann ML; Frangou CG; Wahl GM; Morris RE; Strand V; Kirschbaum BJ
Clin Immunol; 1999 Dec; 93(3):198-208. PubMed ID: 10600330
[TBL] [Abstract][Full Text] [Related]
4. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Breedveld FC; Dayer JM
Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.
Sanders S; Harisdangkul V
Am J Med Sci; 2002 Apr; 323(4):190-3. PubMed ID: 12003373
[TBL] [Abstract][Full Text] [Related]
6. Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Leban J; Vitt D
Arzneimittelforschung; 2011; 61(1):66-72. PubMed ID: 21355448
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of leflunomide in rheumatoid arthritis.
Fox RI
J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
[TBL] [Abstract][Full Text] [Related]
9. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
[TBL] [Abstract][Full Text] [Related]
10. [Leflunomide--a new drug for pharmacological immunomodulation].
Wozel G; Pfeiffer C
Hautarzt; 2002 May; 53(5):309-15. PubMed ID: 12063741
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of leflunomide in active rheumatoid arthritis.
Smolen JS; Emery P
Rheumatology (Oxford); 2000 Jun; 39 Suppl 1():48-56. PubMed ID: 11001380
[TBL] [Abstract][Full Text] [Related]
12. The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review.
Schattenkirchner M
Immunopharmacology; 2000 May; 47(2-3):291-8. PubMed ID: 10878295
[TBL] [Abstract][Full Text] [Related]
13. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
14. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide: dermatologic perspective.
Sehgal VN; Verma P
J Dermatolog Treat; 2013 Apr; 24(2):89-95. PubMed ID: 21801113
[TBL] [Abstract][Full Text] [Related]
16. Leflunomide for rheumatoid arthritis.
Drug Ther Bull; 2000 Jul; 38(7):52-4. PubMed ID: 11027115
[TBL] [Abstract][Full Text] [Related]
17. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
Sawamukai N; Saito K; Yamaoka K; Nakayamada S; Ra C; Tanaka Y
J Immunol; 2007 Nov; 179(10):6479-84. PubMed ID: 17982036
[TBL] [Abstract][Full Text] [Related]
18. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Fragoso YD; Brooks JB
Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
[TBL] [Abstract][Full Text] [Related]
19. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis.
Alldred A; Emery P
Expert Opin Pharmacother; 2001 Jan; 2(1):125-37. PubMed ID: 11336574
[TBL] [Abstract][Full Text] [Related]
20. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]